Definitive Contract HHSN271201600007C

This federal contract was awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Cairn Biosciences Inc., a woman-owned small business, for the development of a microfluidic-enabled smartplate for precision culture, control, and monitoring of living cells. The contract, awarded under the Small Business Innovation Research (SBIR) Program Phase II, has a firm fixed price of $1,499,968.00 and a completion date of May 31, 2020. The contract was...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a Small Business Innovation Research (SBIR) Phase I contract to Cairn Biosciences Inc., a woman-owned small business, for the development of a microfluidic and machine learning-enabled smart laboratory system for autonomous remote execution and iteration of multiscale live cell assays for drug discovery. The firm-fixed-price contract has a potential value of...

<p>This is a $229,893.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Cairn Biosciences Inc., a woman-owned small business. The contract is for the development of a &quot;MULTIPLEXED HIGH CONTENT ASSAY FOR TOXICITY MECHANISMS AND PHENOTYPES IN LIVE IPSC-DERIVED CARDIAC CELLS.&quot; The contract is a definitive, firm-fixed price contract with a completion date of May 14, 2017.</p>

<p>The National Center for Advancing Translational Sciences, a civilian agency, awarded a Firm Fixed Price definitive contract worth $225,000.00 to Cairn Biosciences Inc., a Woman Owned Small Business, for the development of a &quot;MULTIPLEXED HIGH CONTENT ASSAY TO MEASURE ENDOPLASMIC RETICULUM STRESS FOR PREDICTIVE TOXICOLOGY&quot;. The contract has a total small business set-aside and is scheduled for completion by March 14, 2016.</p>

This is a $1,499,999.00 Firm Fixed Price contract awarded by the National Institute on Drug Abuse, a civilian agency, to Cairn Biosciences Inc., a woman-owned small business, for the development of a Multiplexed High-Content Assay to Measure Cellular Stress Mechanisms for Predictive Toxicology Studies. The contract was awarded under the SBIR Program Phase II and has a total small business set-aside designation. The contract was awarded on September 13, 2016 with an ultimate completion date of...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...

This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI) to Biofluidica, Inc., a for-profit organization located in Baton Rouge, Louisiana. The contract has a ceiling value of $199,517.00 and is a Firm Fixed Price Definitive Contract. The contract was awarded on September 30, 2010 with an ultimate completion date of August 29, 2011. As an SBIR Phase I contract, this award supports early-stage research and development efforts.

This is a $1,648,645.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc. under the Small Business Innovation Research (SBIR) Phase II program. The purpose of this contract is to focus on developing a T-cell activation protocol consistent with reporter cell viability, creating a proprietary reporter cell line, and gathering and benchmarking...